Image courtesy by QUE.com As we move through 2026, the intersection of blockchain technology and quantum computing has moved ...

Kairos-HomeWorld is purpose built for embodied intelligence and represents the first unified framework capable of ...

HomeWorld, described as the first unified framework capable of generating a complete, fully interactive home environment from ...

Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs required to develop brand-new drugs have increased in recent decades. It can ...

We are providing an unedited version of this manuscript to give early access to its findings. Before final publication, the manuscript will undergo further editing. Please note there may be errors ...

Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...

Christopher Gibson, Co-Founder and CEO, announced, "beginning January 1, the amazing Najat Khan is going to take over the role of CEO, President and Director of Recursion." Gibson will transition to ...

Forbes contributors publish independent expert analyses and insights. Dr. Lance B. Eliot is a world-renowned AI scientist and consultant. In today’s column, I examine the belief that AI will ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Know how to get the most out of your predictive tools. by Michael Luca, Jon Kleinberg and Sendhil Mullainathan Most managers’ jobs involve making predictions. When HR specialists decide whom to hire, ...

The cognitive processes driving social media use could be key to understanding social media’s impact. Here, the authors develop a computational model of real-world social media behaviour, identifying ...

Recursion Pharmaceuticals to update on FDA trial design for REC-4881 for FAP in the second half of 2026. Analysts expect potential upside from rare diseases.